S&P 500   4,071.77 (-0.20%)
DOW   34,334.69 (-0.74%)
QQQ   293.49 (+0.04%)
AAPL   147.78 (-0.17%)
MSFT   254.29 (-0.33%)
META   120.14 (+1.73%)
GOOGL   101.18 (+0.19%)
AMZN   96.19 (-0.36%)
TSLA   194.70 (+0.00%)
NVDA   171.20 (+1.16%)
NIO   12.34 (-3.44%)
BABA   86.48 (-1.23%)
AMD   77.06 (-0.73%)
T   19.16 (-0.62%)
MU   55.61 (-3.54%)
CGC   3.68 (+1.66%)
F   14.15 (+1.80%)
GE   85.98 (+0.01%)
DIS   98.07 (+0.20%)
AMC   8.48 (+17.29%)
PYPL   78.53 (+0.15%)
PFE   50.69 (+1.12%)
NFLX   316.50 (+3.59%)
S&P 500   4,071.77 (-0.20%)
DOW   34,334.69 (-0.74%)
QQQ   293.49 (+0.04%)
AAPL   147.78 (-0.17%)
MSFT   254.29 (-0.33%)
META   120.14 (+1.73%)
GOOGL   101.18 (+0.19%)
AMZN   96.19 (-0.36%)
TSLA   194.70 (+0.00%)
NVDA   171.20 (+1.16%)
NIO   12.34 (-3.44%)
BABA   86.48 (-1.23%)
AMD   77.06 (-0.73%)
T   19.16 (-0.62%)
MU   55.61 (-3.54%)
CGC   3.68 (+1.66%)
F   14.15 (+1.80%)
GE   85.98 (+0.01%)
DIS   98.07 (+0.20%)
AMC   8.48 (+17.29%)
PYPL   78.53 (+0.15%)
PFE   50.69 (+1.12%)
NFLX   316.50 (+3.59%)
S&P 500   4,071.77 (-0.20%)
DOW   34,334.69 (-0.74%)
QQQ   293.49 (+0.04%)
AAPL   147.78 (-0.17%)
MSFT   254.29 (-0.33%)
META   120.14 (+1.73%)
GOOGL   101.18 (+0.19%)
AMZN   96.19 (-0.36%)
TSLA   194.70 (+0.00%)
NVDA   171.20 (+1.16%)
NIO   12.34 (-3.44%)
BABA   86.48 (-1.23%)
AMD   77.06 (-0.73%)
T   19.16 (-0.62%)
MU   55.61 (-3.54%)
CGC   3.68 (+1.66%)
F   14.15 (+1.80%)
GE   85.98 (+0.01%)
DIS   98.07 (+0.20%)
AMC   8.48 (+17.29%)
PYPL   78.53 (+0.15%)
PFE   50.69 (+1.12%)
NFLX   316.50 (+3.59%)
S&P 500   4,071.77 (-0.20%)
DOW   34,334.69 (-0.74%)
QQQ   293.49 (+0.04%)
AAPL   147.78 (-0.17%)
MSFT   254.29 (-0.33%)
META   120.14 (+1.73%)
GOOGL   101.18 (+0.19%)
AMZN   96.19 (-0.36%)
TSLA   194.70 (+0.00%)
NVDA   171.20 (+1.16%)
NIO   12.34 (-3.44%)
BABA   86.48 (-1.23%)
AMD   77.06 (-0.73%)
T   19.16 (-0.62%)
MU   55.61 (-3.54%)
CGC   3.68 (+1.66%)
F   14.15 (+1.80%)
GE   85.98 (+0.01%)
DIS   98.07 (+0.20%)
AMC   8.48 (+17.29%)
PYPL   78.53 (+0.15%)
PFE   50.69 (+1.12%)
NFLX   316.50 (+3.59%)
NASDAQ:CPIX

Cumberland Pharmaceuticals - CPIX Stock Forecast, Price & News

$2.24
-0.03 (-1.32%)
(As of 12/1/2022 11:33 AM ET)
Add
Compare
Today's Range
$2.24
$2.33
50-Day Range
$2.22
$2.60
52-Week Range
$1.89
$7.51
Volume
560 shs
Average Volume
15,330 shs
Market Capitalization
$32.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Cumberland Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.26mentions of Cumberland Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
Acquiring Shares
$3,456 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

Medical Sector

949th out of 1,047 stocks

Pharmaceutical Preparations Industry

462nd out of 512 stocks

CPIX stock logo

About Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Receive CPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cumberland Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPIX Stock News Headlines

Cumberland Pharmaceuticals Reports 41% Revenue Growth
See More Headlines
Receive CPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cumberland Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPIX Company Calendar

Last Earnings
8/10/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/14/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:CPIX
CUSIP
23077010
Employees
83
Year Founded
1999

Profitability

Net Income
$-3,510,000.00
Pretax Margin
-18.31%

Debt

Sales & Book Value

Annual Sales
$35.99 million
Cash Flow
$0.29 per share
Book Value
$2.63 per share

Miscellaneous

Free Float
8,277,000
Market Cap
$32.84 million
Optionable
Optionable
Beta
0.28

Social Links


Key Executives

  • Mr. A. J. Kazimi MBA (Age 64)
    Founder, Chairman, Pres & CEO
    Comp: $872.63k
  • Mr. John Michael Hamm (Age 65)
    Sr. Director of Fin. & Accounting and CFO
    Comp: $304.91k
  • Mr. James Lowrance Herman (Age 67)
    Exec. VP of National Accounts & Chief Compliance Officer
    Comp: $320.65k
  • Ms. Jean W. Marstiller (Age 72)
    Sr. VP of Admin. Services & Corp. Sec.
  • Ms. Cindy B. Patton (Age 69)
    Sr. Director of Field Marketing
  • Mr. Adam S. Mostafa (Age 42)
    Managing Director
  • Mr. Todd M. Anthony
    VP of Organizational Devel.
  • Ms. Erin Smith Gull
    Sr. Corp. Relations Associate













CPIX Stock - Frequently Asked Questions

How have CPIX shares performed in 2022?

Cumberland Pharmaceuticals' stock was trading at $4.67 on January 1st, 2022. Since then, CPIX shares have decreased by 51.4% and is now trading at $2.27.
View the best growth stocks for 2022 here
.

When is Cumberland Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our CPIX earnings forecast
.

How were Cumberland Pharmaceuticals' earnings last quarter?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) issued its earnings results on Tuesday, August, 10th. The specialty pharmaceutical company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.17. The specialty pharmaceutical company earned $9.06 million during the quarter, compared to analysts' expectations of $8.57 million. Cumberland Pharmaceuticals had a negative net margin of 16.93% and a negative trailing twelve-month return on equity of 1.86%.

What is A. J. Kazimi's approval rating as Cumberland Pharmaceuticals' CEO?

9 employees have rated Cumberland Pharmaceuticals Chief Executive Officer A. J. Kazimi on Glassdoor.com. A. J. Kazimi has an approval rating of 9% among the company's employees. This puts A. J. Kazimi in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cumberland Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cumberland Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), CymaBay Therapeutics (CBAY), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Akero Therapeutics (AKRO), Cerecor (CERC), Xeris Biopharma (XERS).

What is Cumberland Pharmaceuticals' stock symbol?

Cumberland Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPIX."

Who are Cumberland Pharmaceuticals' major shareholders?

Cumberland Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (4.07%), Two Sigma Investments LP (0.31%) and Two Sigma Advisers LP (0.17%). Insiders that own company stock include A J Kazimi, A J Kazimi, Caroline Young, Gordon R Bernard, Joseph C Galante, Kenneth Krogulski, Martin E Cearnal, Martin E Cearnal and William Sumas.
View institutional ownership trends
.

How do I buy shares of Cumberland Pharmaceuticals?

Shares of CPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cumberland Pharmaceuticals' stock price today?

One share of CPIX stock can currently be purchased for approximately $2.27.

How much money does Cumberland Pharmaceuticals make?

Cumberland Pharmaceuticals (NASDAQ:CPIX) has a market capitalization of $33.28 million and generates $35.99 million in revenue each year. The specialty pharmaceutical company earns $-3,510,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.

How can I contact Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals' mailing address is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. The official website for the company is www.cumberlandpharma.com. The specialty pharmaceutical company can be reached via phone at (615) 255-0068, via email at investors@cumberlandpharma.com, or via fax at 615-255-0094.

This page (NASDAQ:CPIX) was last updated on 12/1/2022 by MarketBeat.com Staff